Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
EPZM.US
id: 502
Epizyme Takeover by Ipsen Case
On June 27, 2022, Ipsen (Euronext: IPN; ADR: IPSEY) and Epizyme (Nasdaq: EPZM) announced that they have entered into a definitive merger agreement under which Ipsen will acquire Epizyme. The transaction was unanimously approved by both Ipsen and Epizyme Boards of Directors.
On August 12, 2022, Ipsen announced that acquired all outstanding shares of EPZM for $1.45 per share plus a contingent value right (CVR) of $1.00 per share.
The EPZM's average stock price in the preceding 52 weeks was around $4.5 and had been reaching $10 per share just 1 year ago which makes the deal price unreasonably low.
Taking the preceding price range and analyst valuations into account, Shareholders have grounds to believe that the Board of Directors breached its fiduciary duties by unanimously approving the deal with understated commercial terms.
Case Status
Attorney Investigation
Alleged Offence
Mismanagement,
Misleading Statements,
Financial Misrepresentation,
Failure to Disclose,
Malpractice,
Negligence,
Breach of Fiduciary duty,
Omissions
Suspected Party
Directors,
Management,
Shareholder,
Investment Bank,
Service Provider
Security Type
Stocks
Trade Direction
Long
Shock Event Date
27 June 2022